-- （更新：默克公司對置評請求的回應。） 根據路透社週三引述知情人士報道，德國默克集團（Merck KGaA）和日本小野藥品工業株式會社（Ono Pharmaceutical）已對Inhibrx Biosciences（INBX）的實驗性抗癌藥物表示出興趣，該藥物估值可能超過80億美元。 知情人士告訴路透社，Inhibrx正在考慮聯合剝離該療法INBRX-106以及另一種實驗性抗癌藥物，如果臨床試驗成功，這兩種藥物的總價值可能超過90億美元。 Inhibrx和默克拒絕就此事向置評，而小野藥品工業株式會社尚未回覆置評請求。 （市場閒談新聞來自與全球市場專業人士的對話。這些資訊被認為是來自可靠來源，但可能包含傳聞和猜測。準確性無法保證。）
Price: $112.63, Change: $+0.07, Percent Change: +0.06%
Clinuvel Pharmaceuticals (ASX:CUV) is unlikely to seek regulatory approval for Scenesse in vitiligo until the Phase 3 CUV105 and CUV107 clinical trials are completed, according to a Friday Jefferies note.The company said on Friday that the European Medicines Agency (EMA) has proposed evaluating the company's Scenesse drug for the treatment of systemic vitiligo based on a "totality of evidence" regulatory approach.Jefferies said that the EMA's decision is a positive for the company because of the high unmet medical need for Vitiligo treatment.The investment firm has pushed back its revenue expectations from Scenesse in vitiligo, which is now expected to begin in the second half of fiscal 2029 rather than fiscal 2028.Jefferies kept a buy rating on Clinuvel and cut its price target to AU$39.20 from AU$40.50.
Australian shares are set to open flat on Monday, as oil prices climbed almost 2% following stalled US-Iran peace negotiations and restricted flows through the Strait of Hormuz, tightening global supply and pushing Brent crude above $107 a barrel.On April 25, the S&P 500 and the Nasdaq Composite rose 0.8% and 1.6%, respectively, while the Dow Jones Industrial Average fell 0.2%.In the macroeconomy, investors are eyeing the release of Australia's consumer price index report on Wednesday.In corporate news, Origin Energy (ASX:ORG) reported March quarter production of 164.5 petajoules, down from 167.1 petajoules a year earlier, according to a Monday filing with the Australian bourse.IperionX's (ASX:IPX) titanium powder production operations in Virginia, US, transitioned to an around-the-clock production schedule during the March quarter, advancing from commissioning to continuous operations, according to a Monday filing with the Australian bourse.Australia's benchmark index fell 0.1% or 6.9 points to close at 8,786.50 on April 24.
Cobre (ASX:CBE) has appointed Kaveen Bachoo as chief financial officer, effective April 28, according to a Monday filing with the Australian bourse.Bachoo has over 20 years of finance leadership experience in the mining sector, including executive positions at Glencore.